Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swiss (SMI) Clinical Research and Equipment Industry Analysis

UpdatedApr 17, 2026
DataAggregated Company Financials
Companies7
  • 7D6.3%
  • 3M-3.5%
  • 1Y2.4%
  • YTDn/a

All of the companies in the Clinical Research and Equipment industry have been up over the last week, with the industry up 6.3%. Overall in the last year, the industry is flat. As for the next few years, earnings are expected to grow by 19% per annum.

Industry Valuation and Performance

Has the Swiss Clinical Research and Equipment Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 17 Apr 2026CHF 50.1bCHF 10.1bCHF 1.1b35.4x43.9x5x
Sun, 15 Mar 2026CHF 45.3bCHF 10.1bCHF 1.3b29.1x34.8x4.5x
Tue, 10 Feb 2026CHF 49.4bCHF 10.1bCHF 1.3b32.5x38.8x4.9x
Thu, 08 Jan 2026CHF 50.6bCHF 10.6bCHF 1.1b31.1x46.1x4.8x
Sat, 06 Dec 2025CHF 49.1bCHF 10.7bCHF 1.1b28.6x44.7x4.6x
Mon, 03 Nov 2025CHF 50.7bCHF 10.6bCHF 1.1b31x46.1x4.8x
Wed, 01 Oct 2025CHF 48.8bCHF 10.6bCHF 1.1b30.7x44.4x4.6x
Fri, 29 Aug 2025CHF 53.3bCHF 10.7bCHF 1.1b34.7x48.3x5x
Sun, 27 Jul 2025CHF 54.6bCHF 10.6bCHF 1.1b37.5x48x5.1x
Tue, 24 Jun 2025CHF 52.4bCHF 10.1bCHF 1.0b32.9x50.5x5.2x
Thu, 22 May 2025CHF 52.5bCHF 10.1bCHF 1.0b32.2x50.5x5.2x
Sat, 19 Apr 2025CHF 49.4bCHF 10.1bCHF 1.0b28.1x48.2x4.9x
Mon, 17 Mar 2025CHF 52.1bCHF 10.1bCHF 1.0b33.2x51.2x5.2x
Wed, 12 Feb 2025CHF 58.0bCHF 10.1bCHF 1.0b36x57.6x5.7x
Fri, 10 Jan 2025CHF 54.6bCHF 10.2bCHF 943.4m36x57.9x5.3x
Sun, 08 Dec 2024CHF 52.6bCHF 10.2bCHF 943.7m39.5x55.8x5.2x
Tue, 05 Nov 2024CHF 55.5bCHF 10.2bCHF 943.4m43.4x58.8x5.4x
Thu, 03 Oct 2024CHF 55.3bCHF 10.2bCHF 943.5m42.2x58.6x5.4x
Sat, 31 Aug 2024CHF 57.7bCHF 10.2bCHF 937.0m45.4x61.6x5.7x
Mon, 29 Jul 2024CHF 59.4bCHF 10.2bCHF 923.2m45.3x64.3x5.8x
Wed, 26 Jun 2024CHF 51.6bCHF 10.3bCHF 1.0b44.1x51.4x5x
Fri, 24 May 2024CHF 54.6bCHF 10.3bCHF 1.0b45.3x54.5x5.3x
Sun, 21 Apr 2024CHF 53.1bCHF 10.3bCHF 1.0b43.3x53x5.2x
Tue, 19 Mar 2024CHF 53.2bCHF 10.2bCHF 1.0b44.9x52.9x5.2x
Thu, 15 Feb 2024CHF 50.1bCHF 10.2bCHF 1.0b44.7x49.1x4.9x
Sat, 13 Jan 2024CHF 42.4bCHF 9.8bCHF 1.5b32x28.4x4.3x
Mon, 11 Dec 2023CHF 39.3bCHF 9.8bCHF 1.5b29.9x26.3x4x
Wed, 08 Nov 2023CHF 39.2bCHF 9.8bCHF 1.5b27.7x26.2x4x
Fri, 06 Oct 2023CHF 45.5bCHF 9.8bCHF 1.5b31.4x30.5x4.7x
Sun, 03 Sep 2023CHF 53.4bCHF 9.8bCHF 1.5b36.9x35.8x5.5x
Tue, 01 Aug 2023CHF 53.9bCHF 9.8bCHF 1.5b36.5x34.9x5.5x
Thu, 29 Jun 2023CHF 53.5bCHF 9.7bCHF 1.6b34.7x32.7x5.5x
Sat, 27 May 2023CHF 60.0bCHF 9.7bCHF 1.6b37.6x36.7x6.2x
Mon, 24 Apr 2023CHF 60.7bCHF 9.7bCHF 1.7b42.8x36.4x6.3x
Price to Earnings Ratio

36.4x


Total Market Cap: CHF 60.7bTotal Earnings: CHF 1.7bTotal Revenue: CHF 9.7bTotal Market Cap vs Earnings and Revenue0%0%0%
Swiss Clinical Research and Equipment Industry Price to Earnings3Y Average 46.1x202420252026
Current Industry PE
  • Investors are relatively neutral on the Swiss Life Sciences Tools and Services industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PE ratio of 46.1x.
  • The industry is trading close to its 3-year average PS ratio of 5.1x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences Tools and Services industry have declined 12% per year over the last three years.
  • Meanwhile revenues have remained mostly flat.
  • This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Comparison

How does Swiss Clinical Research and Equipment compare with similar industries?

CH Market0.33%
Healthcare-1.03%
Life Sciences6.30%
Clinical Research and Equipment6.30%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
LONN Lonza GroupCHF 543.405.5%
+CHF 2.0b		0.8%PE41.8x
BANB Bachem HoldingCHF 70.155.7%
+CHF 284.8m		48.2%PE35.3x
SFZN Siegfried HoldingCHF 84.056.5%
+CHF 225.6m		-5.5%PE21.8x
PPGN PolyPeptide GroupCHF 36.2514.5%
+CHF 151.8m		117.1%PS3.3x
SKAN SKAN GroupCHF 49.3511.0%
+CHF 110.2m		-21.4%PE68.2x

Latest News

TECN
CHF 138.00
Tecan Group
7D
2.3%
1Y
-2.8%
BANB
CHF 70.15
Bachem Holding
7D
5.7%
1Y
48.2%

BANB: Future Upside Will Depend On Executing Profit Margin Assumptions

Narrative Update Bachem Holding's updated analyst price target now reflects a modest recalibration in assumptions, with recent CHF 5, CHF 80, and CHF 32 target increases cited by analysts who point to slightly higher profit margin expectations and a small adjustment to the assumed P/E multiple as key drivers. Analyst Commentary Recent research updates on Bachem Holding have leaned constructive, with bullish analysts adjusting their price targets upward and citing a mix of valuation and execution factors.
LONN
CHF 543.40
Lonza Group
7D
5.5%
1Y
0.8%
SKAN
CHF 49.35
SKAN Group
7D
11.0%
1Y
-21.4%
XLS
CHF 22.90
Xlife Sciences
7D
6.5%
1Y
14.5%
SFZN
CHF 84.05
Siegfried Holding
7D
6.5%
1Y
-5.5%

SFZN: Lower Street Expectations Will Support Future Upside Potential

Analysts now see Siegfried's fair value aligning with a lower Street view, with a key price target reset to CHF 96 from CHF 108 as they highlight more balanced expectations following the recent downgrade. Analyst Commentary Recent Street commentary around Siegfried reflects a more cautious stance, with price targets reset and ratings adjusted to align expectations more closely with current execution and valuation risks.
PPGN
CHF 36.25
PolyPeptide Group
7D
14.5%
1Y
117.1%